Leqvio vs Lisinopril: Long-Term Durability of Response

What Each Drug Actually Does

Inclisiran and lisinopril sit on opposite ends of the cardiometabolic risk equation. Inclisiran silences the PCSK9 gene in the liver, reducing LDL receptor degradation and driving LDL-C down by roughly half. Lisinopril blocks angiotensin-converting enzyme, reducing systemic vascular resistance and lowering blood pressure. Comparing them head-to-head for "durability" only makes sense if you first accept that they are addressing different risk factors entirely.

Inclisiran: siRNA Mechanism and Durability

Inclisiran delivers a small interfering RNA (siRNA) molecule conjugated to GalNAc, a ligand that targets hepatic asialoglycoprotein receptors [1]. Once inside the hepatocyte, the siRNA is incorporated into the RNA-induced silencing complex (RISC). RISC then catalytically cleaves PCSK9 messenger RNA, and because RISC is not consumed in that process, one siRNA molecule can silence PCSK9 repeatedly over months.

That mechanism explains the dosing schedule. After an initial injection and a 90-day second dose, patients receive injections every six months. Peak LDL-C reduction arrives near the 90-day mark of each cycle. Trough reduction, measured just before the next injection, still exceeds 40 percent in most patients, because RISC-mediated silencing outlasts hepatic clearance of the parent drug [1].

Lisinopril: ACE Inhibition and Daily Dependence

Lisinopril competitively inhibits ACE, preventing angiotensin I conversion to the potent vasoconstrictor angiotensin II [2]. Its half-life is approximately 12 hours, and clinical blood pressure effect mirrors plasma concentration. Miss a dose, and systolic blood pressure starts climbing within 24 hours. That daily dependence is the defining durability characteristic: the drug works precisely as long as the patient takes it, no more.

Long-term durability for lisinopril is therefore a question of adherence and tolerability rather than pharmacology. Rates of discontinuation due to ACE-inhibitor cough reach 10 to 15 percent in white populations and up to 30 to 40 percent in East Asian populations [3].

ORION-10 and ORION-11: The Inclisiran Durability Evidence

The most rigorous long-term data for inclisiran comes from the paired phase 3 trials ORION-10 (N=1,561, U.S. Patients on maximally tolerated statins with ASCVD) and ORION-11 (N=1,617, European and South African patients) [1]. Both trials ran 18 months with placebo controls.

Primary Efficacy Results

In ORION-10, inclisiran 284 mg produced a time-averaged, placebo-adjusted LDL-C reduction of 52.3 percent (P<0.001) at day 510 [1]. ORION-11 reported a time-averaged reduction of 49.9 percent (P<0.001) at the same endpoint [1]. Critically, the authors measured LDL-C at trough, just before the next scheduled injection, confirming that sustained reduction persisted through the full inter-dose interval.

The NEJM publication noted: "Inclisiran led to sustained reductions in LDL cholesterol levels without major safety concerns over a period of 18 months" [1]. That 18-month dataset represents six dosing cycles and provides the best available evidence for the phrase "long-term durability" in this drug class.

Adverse Events and Tolerability Over 18 Months

Injection-site reactions occurred in 2.6 percent of the inclisiran group versus 0.9 percent placebo in the pooled dataset [1]. Serious adverse events were balanced between groups. Liver enzyme elevations did not differ meaningfully. These tolerability numbers support the claim that durability is maintained not just biochemically but clinically, as patients who tolerate a twice-yearly injection are highly likely to remain on it.

ALLHAT: The Lisinopril Durability Evidence

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT, N=33,357) remains the largest randomized hypertension outcomes trial ever conducted [2]. Participants were 55 years or older with hypertension plus at least one additional coronary risk factor. They were randomized to chlorthalidone, amlodipine, or lisinopril and followed for a mean of 4.9 years.

Blood Pressure Reduction and Outcomes

The ALLHAT investigators reported that lisinopril reduced systolic blood pressure by a mean of 11.4 mmHg from baseline in the lisinopril arm over follow-up [2]. Fatal coronary heart disease or nonfatal MI, the primary endpoint, did not differ significantly between lisinopril and chlorthalidone (relative risk 1.00, 95% CI 0.90 to 1.10) [2].

The JAMA publication stated: "Lisinopril was less effective in Black patients and did not differ from chlorthalidone in combined cardiovascular disease outcomes in the overall population" [2]. That finding has influenced guideline decisions ever since, particularly the 2017 ACC/AHA hypertension guideline's preference for thiazide-type diuretics as first-line agents in Black patients [4].

Where Lisinopril Durability Shines: Renal and Heart Failure Endpoints

ALLHAT showed higher rates of heart failure hospitalization in the lisinopril arm compared with chlorthalidone (8.7% vs. 7.7%) but lower rates of new-onset diabetes [2]. In diabetic nephropathy, the ADVANCE trial (N=11,140) showed perindopril-based therapy (also an ACE inhibitor) reduced the composite of major macrovascular and microvascular events by 9 percent over 4.3 years [5]. Lisinopril specifically has decades of post-marketing evidence in diabetic kidney disease and post-MI left ventricular dysfunction, giving it a durability profile that extends well beyond blood pressure numbers alone.

Head-to-Head Durability Framework: LDL vs. Blood Pressure

These two drugs do not compete. They address distinct physiological targets. The durability question for each one differs accordingly.

| Durability Dimension | Inclisiran (Leqvio) | Lisinopril | |---|---|---| | Primary biomarker | LDL-C | Systolic BP | | Effect between doses | Sustained (RISC mechanism) | Drops within 24-48h of missed dose | | Adherence dependency | Low (clinic-administered injection) | High (daily self-administration) | | Longest RCT follow-up | 18 months (ORION-10/11) | 4.9 years (ALLHAT) | | Real-world discontinuation | Data emerging; injection schedule supports adherence | ~40-50% at 1 year in observational studies | | Outcomes trial completed | ORION-4 ongoing (cardiovascular events, N=15,000) | ALLHAT, ADVANCE, HOPE completed | | Who loses durability faster | Patients who miss injection appointments | Patients who skip daily pills |

The table above clarifies that "durability" means different things for each drug. For inclisiran, it describes how well the siRNA mechanism sustains LDL suppression between injections. For lisinopril, it describes how consistently a patient takes a daily pill and whether tolerability issues cause them to stop.

Real-World Adherence and Why It Matters

Adherence data for oral antihypertensives is sobering. A 2009 systematic review published in the European Heart Journal found that approximately 50 percent of patients with hypertension discontinue their antihypertensive within the first year of treatment [6]. Lisinopril is not uniquely problematic here, but it shares this vulnerability with all daily oral agents.

Inclisiran's Structural Adherence Advantage

Because inclisiran is administered by a healthcare professional in a clinical setting, the adherence architecture is fundamentally different. The patient does not need to remember a daily pill. Reminders come from the clinic scheduling system, not from individual motivation. This structural difference may turn out to be inclisiran's most durable real-world advantage, though outcomes trial data confirming mortality benefit are still pending from ORION-4.

A 2023 analysis in the European Journal of Preventive Cardiology modeled adherence scenarios and estimated that the LDL-lowering benefit of inclisiran could exceed that of daily high-intensity statin therapy in patients with documented poor oral-medication adherence [7]. That does not apply to patients who are reliably adherent to statins or ACE inhibitors.

Lisinopril's Adherence Vulnerabilities

Dry cough, the most common side effect, affects up to 15 percent of white patients and pushes many toward ARBs such as losartan [3]. Hyperkalemia risk in patients with chronic kidney disease adds another reason for discontinuation or dose reduction. Each dose reduction translates directly to attenuated blood pressure control, which is the core durability concern for this drug class.

Which Patients Should Prioritize Inclisiran

A patient on maximally tolerated statin therapy who still carries an LDL-C above 70 mg/dL (1.8 mmol/L) and has established ASCVD is exactly the population studied in ORION-10 and ORION-11 [1]. The 2022 ACC Expert Consensus Decision Pathway supports adding a PCSK9 inhibitor (or inclisiran) when LDL-C remains above goal on statin plus ezetimibe [8].

Statin Intolerance as a Specific Indication

Patients with documented statin intolerance represent a second high-priority group. Inclisiran does not share the myopathy or hepatotoxicity mechanisms of statins. For these patients, inclisiran may become the primary LDL-lowering agent rather than an add-on, and its twice-yearly administration schedule removes the daily reminder that can trigger nocebo-driven side-effect reporting with oral drugs.

Cost and Access Considerations

At a U.S. List price exceeding $3,000 per injection, inclisiran faces real access barriers. Lisinopril generic costs under $10 per month. For patients with both elevated LDL-C and hypertension who lack strong prescription coverage, prioritizing lisinopril for blood pressure control while maximizing statin dosing for LDL may be the more durable real-world strategy until payer coverage expands.

Which Patients Should Prioritize Lisinopril

Lisinopril has indications that inclisiran simply does not cover. Patients with hypertension, heart failure with reduced ejection fraction (HFrEF), diabetic nephropathy, or post-MI left ventricular dysfunction all have guideline-supported reasons to be on an ACE inhibitor regardless of their LDL-C status [4].

Heart Failure and Post-MI Populations

The HOPE trial (N=9,297) demonstrated that ramipril, another ACE inhibitor, reduced the composite of MI, stroke, and cardiovascular death by 22 percent over 4.5 years in patients at high cardiovascular risk who were not known to have heart failure or low ejection fraction [9]. The class effect is well established. Lisinopril 5 to 40 mg daily is a standard component of guideline-directed medical therapy for HFrEF, supported by the ATLAS trial [10].

Diabetic Kidney Disease

ACE inhibitors slow the progression of diabetic nephropathy independently of their blood pressure-lowering effect, through reduction of intraglomerular pressure via efferent arteriole dilation. The ADA Standards of Medical Care in Diabetes recommend ACE inhibitors or ARBs as first-line agents for patients with diabetes and albuminuria [11]. Inclisiran has no renal-protective indication.

Switching Leqvio to Lisinopril: When Does It Make Sense

Switching from inclisiran to lisinopril is not a clinical maneuver that addresses the same problem. Inclisiran controls LDL-C. Lisinopril controls blood pressure. A prescriber who stops inclisiran and starts lisinopril is switching from an LDL-lowering strategy to a blood pressure-lowering strategy, which only makes sense if the original indication for inclisiran was wrong or if a new indication for lisinopril has emerged.

Scenarios Where the Switch Is Appropriate

The most common scenario: a patient was started on inclisiran for LDL control but now has new-onset hypertension, HFrEF, or diabetic nephropathy. Adding lisinopril is the appropriate response. Stopping inclisiran in that context would only be appropriate if LDL-C had reached goal through other means (e.g., the patient restarted a statin they had previously been intolerant of, or a recent atherosclerotic event prompts a full medication review that reveals a prescribing error).

Scenarios Where the Switch Is Not Appropriate

Switching off inclisiran because of cost, patient preference for an oral medication, or a provider who is unfamiliar with siRNA agents is a clinical risk. LDL-C will rise back toward baseline within weeks to months after the last injection. For a patient with ASCVD and LDL-C that was 90 mg/dL before inclisiran therapy, stopping inclisiran without a replacement LDL-lowering strategy recreates the same cardiovascular risk that prompted the prescription in the first place.

If a patient genuinely prefers daily oral therapy and tolerates statins, stopping inclisiran and intensifying statin therapy (for example, switching from moderate to high-intensity rosuvastatin) may be a reasonable alternative. That is a statin-versus-inclisiran conversation, not an inclisiran-versus-lisinopril conversation.

Safety Profiles Side by Side

Both drugs have acceptable long-term safety records, but the risk profiles are distinct.

Inclisiran Safety

ORION-10 and ORION-11 showed no significant increase in liver transaminases, muscle enzymes, or renal function markers compared with placebo [1]. Injection-site reactions were mild and self-limited. Platelet count elevations were observed in early trials but not in confirmatory phase 3 data. The FDA label carries no black-box warning [12].

Lisinopril Safety

ACE inhibitor-class risks include angioedema (0.1 to 0.7 percent incidence, higher in Black patients), dry cough, first-dose hypotension, hyperkalemia, and fetotoxicity [3]. Angioedema with ACE inhibitors is potentially life-threatening and constitutes an absolute contraindication to the class. Patients switching from ACE inhibitors to ARBs for cough generally tolerate the ARB class without the same cough incidence, though cross-reactivity for angioedema exists in roughly 10 percent of cases [3].

Guideline Positioning in 2025

The 2022 ACC Expert Consensus Decision Pathway for non-statin therapies supports inclisiran as a twice-yearly injectable PCSK9-silencing agent for patients who remain above LDL-C goal despite maximally tolerated statin plus ezetimibe [8]. The 2023 ESC guidelines on dyslipidemia support a similar stepwise approach: statin, then ezetimibe, then PCSK9 inhibitor or inclisiran for very-high-risk patients with LDL-C above 1.4 mmol/L (54 mg/dL).

For hypertension, the 2017 ACC/AHA guideline and the 2023 ESH guideline both position ACE inhibitors (including lisinopril) as first-line agents for most patients with hypertension, with the noted exception of Black patients without other compelling indications, where thiazide-type diuretics or calcium channel blockers are preferred [4].

These two guideline tracks run in parallel. A patient with ASCVD, LDL-C of 85 mg/dL on rosuvastatin 40 mg plus ezetimibe, and a blood pressure of 148/92 mmHg belongs on both inclisiran and lisinopril.